Paradigm Therapeutics, Inc. Announces an Additional Investment by Eshelman Ventures, LLC to Expedite Global Development and Global Registration of SD-101, A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bull
First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used to Accelerate Activities Associated with Increasing Manufacturing Development of SD-101 and Commercial Launch of the...
AccurEdit Therapeutics' ART001 Becomes China's First Gene Editing Therapy to Receive FDA Regenerative Medicine Advanced Therapy (RMAT) Designation
RMAT designation expected to expedite development; 72 weeks interim clinical trial data showing sustainable reduction of TTR over 90% with no significant adverse events. SUZHOU, China, May 29, 2025 /PRNewswire/ -- AccurEdit Therapeutics today...
CRIMSONLOGIC JOINS U.S. CBP'S SECTION 321 DATA PILOT TO DIGITIZE ADVANCE SHIPPER DATA ELEMENTS
This strategic partnership aims to expedite customers clearance and improve risk assessment for low-value shipments. IRVINE, Calif., Dec. 16, 2024 /PRNewswire/ -- Global technology company CrimsonLogic, a wholly-owned subsidiary of PSA...